How is guanfacine classified?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Guanfacine Classification

Guanfacine is classified as a non-stimulant medication for ADHD, specifically functioning as a selective alpha-2A adrenergic receptor agonist. 1

Pharmacological Classification

Guanfacine belongs to the alpha-2 adrenergic agonist class of medications, with high specificity for the alpha-2A receptor subtype. 1 This distinguishes it from clonidine, which is also an alpha-2 agonist but with approximately 10 times greater potency and less receptor selectivity. 1

Mechanism of Action

  • Central alpha-2A receptor agonism in the prefrontal cortex enhances noradrenergic neurotransmission, strengthening regulatory control over attention, working memory, and executive function. 1
  • The drug acts postsynaptically on dendritic spines to inhibit cAMP-PKA-potassium channel signaling, thereby strengthening network connectivity and enhancing prefrontal cortical neuronal firing. 2
  • In the brainstem, alpha-2 agonism reduces peripheral vascular resistance and lowers blood pressure, which was its original therapeutic indication. 1

Therapeutic Classification

Primary Classification

Non-stimulant ADHD medication - Guanfacine is FDA-approved as extended-release formulation for treating ADHD as monotherapy or adjunctive therapy to stimulants. 1

Treatment Position

  • Second-line treatment for ADHD according to current guidelines, with stimulants recommended as first-line therapy due to larger effect sizes. 1
  • In Europe, guanfacine is specifically approved only when stimulants are not suitable, not tolerated, or have been shown ineffective. 1

Additional Therapeutic Uses

  • Antihypertensive agent - Originally FDA-approved for treating hypertension in adolescents and adults. 3, 4
  • Off-label uses include treatment of prefrontal cortical disorders, stress-related disorders, substance abuse, schizotypic cognitive deficits, traumatic brain injury, and pervasive developmental disorders. 2, 4

Regulatory Classification

  • Non-controlled substance - Unlike stimulant ADHD medications, guanfacine has non-controlled status, which represents a practical advantage. 1
  • Available as extended-release tablets in 1,2,3, and 4 mg doses for ADHD treatment. 1

Metabolic Classification

Guanfacine is primarily metabolized via CYP3A4 and excreted predominantly renally, distinguishing it from clonidine which is metabolized via CYP2D6. 1

Clinical Efficacy Profile

  • Medium effect size compared to placebo, generally smaller than stimulants but clinically meaningful. 1
  • Delayed onset of action requiring 2-4 weeks for treatment effects to manifest, unlike stimulants which have rapid onset. 1
  • Provides "around-the-clock" effects with once-daily dosing, typically administered in the evening due to somnolence risk. 1

References

Related Questions

Should guanfacine extended-release (ER) be tapered when discontinuing it?
Can guanfacine cause significant hair loss in a patient with a history of anxiety, gastritis, Attention Deficit Hyperactivity Disorder (ADHD), and hypertension?
Can crying be a side effect of guanfacine in patients with Attention Deficit Hyperactivity Disorder (ADHD) or hypertension?
Can guanfacine (Intuniv) help with intrusive thoughts, also known as obsessive thoughts?
Is guanfacine appropriate for PRN (as‑needed) use?
How should a child with developmental delay due to a chromosome 13 abnormality (trisomy 13 or 13q deletion) be evaluated and managed?
What is the significance of a pause in the cardiac rhythm after inspiration and how should it be evaluated?
How can iron studies be used to differentiate thalassemia from anemia of chronic disease?
What is the appropriate emergency department management for an olecranon avulsion fracture?
In a patient with severe hypovolemia secondary to intra‑abdominal bleeding who develops atrial fibrillation, what is the priority before initiating rate‑control therapy?
After Mirena (levonorgestrel-releasing intrauterine device) insertion, I have yellow gelatinous cervical mucus on days 1‑2, spotting on days 14‑15, and a brief bleed ending by day 28 before the cycle restarts; is this a normal post‑insertion bleeding pattern and how should it be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.